8-K: Akari Therapeutics Secures $2.5M in Direct Offering

Akari Therapeutics raises $2.5 million through a registered direct offering of ADSs and a concurrent private placement of Series E and F warrants to fund R&D.

Summary

• Akari Therapeutics, Plc entered into a securities purchase agreement on October 14, 2025, for a registered direct offering of 3,125,000 American Depositary Shares (ADSs).
• The ADSs were offered and sold at a combined purchase price of $0.80 per ADS, together with Series E and Series F warrants.
• The Series E and F warrants allow for the purchase of up to an aggregate of 3,125,000 ADSs each.
• The aggregate gross proceeds from the offering are expected to be approximately $2.5 million, excluding any future warrant exercises.
• The offering is expected to close on or about October 16, 2025.
• Net proceeds will be used for working capital, general corporate purposes, and continued research and development (R&D), specifically for a novel ADC payload against cancer.
• Series E Warrants have an exercise price of $0.98 per share and a 5-year term from the Shareholder Approval Date.
• Series F Warrants have an exercise price of $0.98 per share and a 30-month term from the Shareholder Approval Date.
• The company agreed to file a registration statement for the resale of ADSs underlying the warrants within 30 days of the closing date.
• Shareholder approval for the issuance of ADSs upon warrant exercise is required and will be sought at a special meeting within 60 days of the closing date, with subsequent meetings every 40 days if not obtained.
• Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent, receiving a 7.2% cash placement fee, a 0.5% cash management fee, and warrants to purchase up to 125,000 ADSs (4.0% of ADSs sold) at an exercise price of $1.00 per share with a 5-year term.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding for R&D and operations, which is positive for a development-stage biotech. However, the significant dilution from the new ADSs and warrants, along with associated fees, tempers the overall positive sentiment, making it a neutral-to-slightly-positive event.

Positives

• Secured approximately $2.5 million in gross proceeds, providing capital for operations and R&D.
• Funds are specifically allocated to generate differentiated data on a novel ADC payload, highlighting a focused R&D strategy in oncology.
• The offering includes both a registered direct offering and a private placement, diversifying financing sources.

Negatives

• The issuance of 3,125,000 ADSs and warrants to purchase an additional 6,250,000 ADSs (plus placement agent warrants) will result in significant dilution for existing shareholders.
• Shareholder approval is required for the issuance of ADSs underlying the warrants, introducing a contingency for full warrant exercisability.
• Substantial fees and expenses are payable to the placement agent, including cash fees totaling 7.7% of gross proceeds and additional warrants.

Risks

• Failure to obtain timely shareholder approval for the issuance of ADSs underlying the warrants could impact the value and exercisability of the warrants.
• The company's ability to maintain compliance with Nasdaq listing requirements, especially concerning shareholder approval, poses a risk.
• Future market conditions could negatively impact the exercise of warrants, affecting potential additional capital inflow.
• The company is prohibited from issuing certain equity or equity equivalents for 30 days and variable rate transactions for one year, limiting financing flexibility during these periods.

Future Outlook

The company intends to use the net proceeds from the offering for working capital, general corporate purposes, and continued research and development. A specific focus is to generate differentiated data on a novel ADC payload to highlight its unique action against cancer, building on new data to be presented at the upcoming Society for Immunotherapy Cancer Society Annual Meeting in early November. The company will also file a registration statement for the resale of warrant ADSs and seek shareholder approval for the warrant issuance.

Management Comments

• Torsten Hombeck, Chief Financial Officer, signed the Form 8-K on behalf of Akari Therapeutics, Plc.

Industry Context

This capital raise is a common financing mechanism for biotechnology companies, particularly those in the R&D phase, to fund ongoing clinical development and operational expenses. Akari Therapeutics' stated use of proceeds for a novel ADC payload in cancer aligns with a significant and competitive area within the pharmaceutical industry, where continuous funding is critical for advancing drug candidates through various development stages.

Comparison to Industry Standards

• The capital raise structure, involving a combination of ADSs and warrants, is a standard approach for biotech companies seeking to raise capital while offering investors potential upside through warrants.
• The placement agent fees (7.2% cash fee + 0.5% management fee + 4.0% warrants) are within the typical range for small to mid-cap biotechnology offerings, reflecting the risk and effort involved in placing such securities.
• The requirement for shareholder approval for warrant exercises is a common corporate governance practice to prevent excessive dilution without investor consent, aligning with industry norms for public companies.

Corporate Governance

Stakeholder Impact

• Shareholders will experience immediate dilution from the issuance of 3,125,000 ADSs and potential future dilution from the exercise of 6,250,000 Series E and F Warrants, plus 125,000 Placement Agent Warrants.
• The capital raise provides critical funding for the company's R&D efforts, which could lead to long-term value creation if the novel ADC payload proves successful.
• The company's employees in R&D may benefit from continued funding for their projects, potentially securing jobs and advancing scientific work.

Next Steps

• The offering is expected to close on or about October 16, 2025.
• The company will file a registration statement for the resale of ADSs issuable upon exercise of the warrants within 30 days of the Closing Date.
• A meeting of shareholders will be called within 60 days of the Closing Date to obtain approval for the issuance of ADSs underlying the warrants.
• If shareholder approval is not obtained, subsequent meetings will be called every 40 days until approval is secured.
• Net proceeds will be deployed for working capital, general corporate purposes, and continued R&D, focusing on a novel ADC payload.

Key Dates

Recommendation

The capital raise is a necessary step for Akari Therapeutics to fund its ongoing research and development, particularly for the novel ADC payload, which is crucial for a biotechnology company. This provides operational runway and supports pipeline advancement. However, the offering involves significant dilution from the issuance of new ADSs and warrants, which will likely put downward pressure on the stock price. The need for shareholder approval for warrant exercises adds a layer of uncertainty. Given the balance between essential funding and dilutive impact, a 'hold' recommendation is appropriate for investors to observe the company's progress with the new capital and the market's absorption of the new shares.

Keywords

Akari Therapeutics, AKTX, SEC filing, 8-K, direct offering, private placement, warrants, ADSs, capital raise, biotechnology, pharmaceutical, R&D, oncology, ADC payload, equity financing, dilution